To Adis journal portfolio news, mid-2016 saw the release of the ISI Journal Citation Reports and the latest journal impact factors. The impact factor for BioDrugs remained relatively stable at 2.867. The majority of our other journals saw a rise in impact factor against the previous year. Most notably, five of our journals saw an increase of over 10% in impact factor-The Patient (17.08%), Clinical Drug Investigation (15.99%), the American Journal of Clinical Dermatology (13.17%), Drug Safety (13.5%), and Drugs (12.43%).
Another important milestone was reached for our recently launched open access journals, Drug Safety-Case Reports and Drugs-Real World Outcomes. Content from these journals is now available on PubMed Central.
The Adis journals portfolio will expand in 2017, with the launch of PharmacoEconomics-Open. This new journal will be fully open access and will focus on the publication of applied research on the economic implications and health outcomes associated with drugs, devices and other healthcare interventions. It joins our other well respected health outcomes publications, PharmacoEconomics, Applied Health Economics and Health Policy, and The Patient: PatientCentered Outcomes Research.
I hope that you have found the articles published throughout 2016 to be both interesting and informative. I have appreciated the high quality of content contributed to the journal this year and I look forward to keeping you up to date with topical issues in the clinical biotechnology field in 2017.
With best wishes from Kathy Fraser, Editor.
